Reduced quantitative ultrasound bone mineral density in HIV-infected patients on antiretroviral therapy in Senegal

• Published in: PloS one 2012-02, Vol.7 (2), p.e31726
• Main Authors: Cournil, Amandine, Eymard-Duvernay, Sabrina, Diouf, Assane, Moquet, Claire, Coutherut, Julie, Ngom Gueye, Ndèye Fatou, Cames, Cécile, Taverne, Bernard, Bork, Kirsten, Sow, Papa Salif, Delaporte, Eric
• Format: Article
• Language: English
• Subjects: Absorptiometry; Acquired immune deficiency syndrome; Adenine - analogs & derivatives; Adenine - pharmacology; Adenine - therapeutic use; Adult; AIDS; Analysis; Anti-HIV Agents; Anti-Retroviral Agents - therapeutic use; Antiretroviral agents; Antiretroviral drugs; Antiretroviral therapy; Biology; Body mass; Body Mass Index; Bone density; Bone Density - drug effects; Bone mineral density; Calcaneus; Calcium; Care and treatment; Case-Control Studies; Confidence intervals; Exercise; Female; Highly active antiretroviral therapy; HIV; HIV infections; HIV Infections - drug therapy; HIV Infections - physiopathology; HIV patients; Human immunodeficiency virus; Humans; Male; Medicine; Middle Aged; Organophosphonates - pharmacology; Organophosphonates - therapeutic use; Patients; Physical activity; Protease; Protease inhibitors; Protease Inhibitors - pharmacology; Protease Inhibitors - therapeutic use; Proteases; Senegal; Smoking; Tenofovir; Ultrasound; Viral Load
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0031726

Bone status in HIV-infected patients on antiretroviral treatment (ART) is poorly documented in resource-limited settings. We compared bone mineral density between HIV-infected patients and control subjects from Dakar, Senegal. A total of 207 (134 women and 73 men) HIV-infected patients from an observational cohort in Dakar (ANRS 1215) and 207 age- and sex-matched controls from the general population were enrolled. Bone mineral density was assessed by quantitative ultrasound (QUS) at the calcaneus, an alternative to the reference method (i.e. dual X-absorptiometry), often not available in resource-limited countries. Mean age was 47.0 (±8.5) years. Patients had received ART for a median duration of 8.8 years; 45% received a protease inhibitor and 27% tenofovir; 84% had undetectable viral load. Patients had lower body mass index (BMI) than controls (23 versus 26 kg/m(2), P